Trial Profile
Safety and Efficacy of Maraviroc, a CCR5-inhibitor in Prophylaxis of Graft-Versus-Host Disease in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 15 Apr 2020 Status changed from active, no longer recruiting to completed.
- 05 Jan 2017 Results of post-hoc analysis published in the Blood.
- 23 Sep 2016 Status changed from completed to active, no longer recruiting.